Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, exhibits, regulation-fd
Related Tickers: APTX
TL;DR
APTX filed an 8-K on 4/1/26, check exhibits for updates.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an interactive data document and exhibits, such as EX-99.1, and is related to their pharmaceutical preparations business.
Why It Matters
This 8-K filing indicates that Aprea Therapeutics is disclosing information under Regulation FD and providing financial statements and exhibits, which could contain updates relevant to investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for disclosure and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 0001104659-26-038258 — SEC Accession Number (Unique identifier for this filing)
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Filer of the 8-K
- 0001781983 (company) — CIK number for Aprea Therapeutics, Inc.
- 2026-04-01 (date) — Filing date and period of report
- Item 7.01 (other) — Regulation FD Disclosure
- Item 9.01 (other) — Financial Statements and Exhibits
FAQ
What specific information is disclosed under Regulation FD?
The filing does not specify the content of the Regulation FD disclosure, only that it is included as Item 7.01.
What types of financial statements or exhibits are included?
The filing lists an interactive data document, EX-99.1, and other graphic and XBRL related files as exhibits.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 1, 2026, at 08:45:47.
What is Aprea Therapeutics' primary business as indicated by the SIC code?
The SIC code 2834 indicates their business is Pharmaceutical Preparations.
What is the CIK number for Aprea Therapeutics, Inc.?
The CIK number for Aprea Therapeutics, Inc. is 0001781983.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2026-04-01 08:45:47
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
- $30 million — ent for gross proceeds of approximately $30 million. The press release is attached hereto a
Filing Documents
- apre-20260401x8k.htm (8-K) — 39KB
- apre-20260401xex99d1.htm (EX-99.1) — 14KB
- apre-20260401xex99d1001.jpg (GRAPHIC) — 5KB
- 0001104659-26-038258.txt ( ) — 179KB
- apre-20260401.xsd (EX-101.SCH) — 3KB
- apre-20260401_def.xml (EX-101.DEF) — 3KB
- apre-20260401_lab.xml (EX-101.LAB) — 16KB
- apre-20260401_pre.xml (EX-101.PRE) — 11KB
- apre-20260401x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 1, 2026, Aprea Therapeutics, Inc. issued a press release regarding the closing of its previously announced private placement for gross proceeds of approximately $30 million. The press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release of Aprea Therapeutics, Inc., dated as of April 1, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: April 1, 2026 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer